NEW YORK (GenomeWeb) – A subset of breast cancers contain mutational signatures consistent with DNA mismatch repair (MMR) deficiency, new research reveals, suggesting that some individuals with the disease may benefit from immune checkpoint blockade immunotherapies similar to those being used in other types of cancer with MMR deficits.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.